Compare Amphastar Pharmaceuticals Inc (AMPH) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Carlyle Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while Carlyle Group Inc trades at $44.11 (market cap $16.09B). The key difference: Carlyle Group Inc is far larger — about 19.5× Amphastar Pharmaceuticals Inc's market cap, and Carlyle Group Inc pays a 3.13% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CG | |
|---|---|---|
Market Cap | $826.08M | $16.09B |
Sector | Health | Financials |
52-Week High | $30.81 | $69.35 |
52-Week Low | $16.87 | $40.52 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CG trades at $44.71, up 1.2% today, with neutral technical signals and mixed earnings performance. The company reported Q1 2026 EPS of $0.89, missing expectations, but maintains a strong analyst consensus with a $60.33 price target. Recent developments include the acquisition of a majority stake in MAI Capital Management and the upcoming Q2 2026 earnings release on August 5, 2026.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic acquisitions, but risks include volatile cash flows from operations and recent earnings misses. Investment opportunity lies in the significant upside to the consensus price target if execution improves, while downside risks stem from operational cash burn and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
